Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone

NCT00059631 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Mitoxantrone (Novantrone)
DRUG: Bortezomib (PS-341)

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]